Abstract:Effective screening is essential to reducing CRC incidence and mortality by detecting the disease at early stages and identifying non-invasive precursors. While colonoscopy remains the most sensitive modality to visualize and remove neoplastic lesions thereby reducing CRC and the related death, its high cost and invasive nature limit its widespread use. The fecal immunochemical test (FIT), which offers a non-invasive alternative with higher public acceptance and comparable cost-effectiveness to colonoscopy, has become the preferred screening method in many regions. Newer non-invasive tests, such as multitarget stool DNA or RNA tests, have shown improved sensitivity for CRC and advanced adenomas, although their high costs and lower specificity present challenges for large-scale implementation. Blood-based circulating cell-free DNA test also offer promise but still require optimization to be cost-effective. The heterogeneity of the screening population further complicates the effectiveness of CRC screening programs. Variations in non-communicable disease risk factors, such as metabolic syndrome, lifestyle habits, and comorbidities, can significantly influence CRC risk and screening outcomes. Moreover, diverse screening behaviors, including inconsistent adherence to recommended screening intervals and the interchangeable use of different screening modalities, add complexity to achieving uniform effectiveness across populations. This variability underscores the need for personalized screening strategies that consider individual risk profiles and screening behaviors, as well as the application of cutting-edge technologies such as big data analytics, artificial intelligence, and digital twin approaches to evaluate its effectiveness. This article reviews the current CRC screening strategies, the advantages of non-invasive methods, and the potential of fecal hemoglobin concentration, to tailor screening intervals and improve risk stratification. It also discusses the emerging role of real-world data and advanced technologies in enhancing CRC screening accuracy and effectiveness, particularly in complex real-world scenarios where traditional methods may fall short. Before novel non-invasive approaches, such as ctDNA tests or polygenic risk scores, are validated and proven cost-effective, exploring the clinical utility of FIT and its quantitative measurement in both screening and surveillance by integrating real-world clinical big data seems a feasible direction for achieving sustained development in population screening.

Stool- and Blood-Based Molecular Tests in Screening for Colorectal Cancer: Ready for Prime Time?

Noninvasive DNA Methylation Biomarkers in Colorectal Cancer: A Systematic Review.

Utility of Stool-Based Tests for Colorectal Cancer Detection: A Comprehensive Review

Stool Based Testing for Colorectal Cancer: an Overview of Available Evidence

Advances in tests for colorectal cancer screening and diagnosis

Stool Investigations for Colorectal Cancer Screening: From Occult Blood Test to DNA Analysis

Emerging stool-based and blood-based non-invasive DNA tests for colorectal cancer screening: the importance of cancer prevention in addition to cancer detection

Projected Impact and Cost-Effectiveness of Novel Molecular Blood-Based or Stool-Based Screening Tests for Colorectal Cancer

Non-Invasive Colorectal Cancer Screening: An Overview

DNA Methylation Biomarkers in Stool Samples: Enhancing Colorectal Cancer Screening Strategies

Clinical, social, and economic impacts of colorectal cancer screening with the multi-target stool-DNA test: 10-year experience - a simulated study

Colorectal Cancer Diagnosis: The Obstacles We Face in Determining a Non-Invasive Test and Current Advances in Biomarker Detection

Towards Novel Non-Invasive Colorectal Cancer Screening Methods: A Comprehensive Review

Adopting Non-invasive Approaches into Precision Colorectal Cancer Screening

Advances in blood DNA methylation-based assay for colorectal cancer early detection: a systematic updated review

A novel multitarget stool DNA test for colorectal cancer screening

Multitarget Stool DNA Test Compared with Fecal Occult Blood Test for Colorectal Cancer Screening

Comparison of Simulated Outcomes Between Stool- and Blood-Based Colorectal Cancer Screening Tests

Next-Generation Screening for Colorectal Cancer, an Incremental Approach to a Global Disease

Optimization of screening strategies for colorectal cancer based on fecal DNA and occult blood testing

Efficacy of cell-free DNA methylation-based blood test for colorectal cancer screening in high-risk population: a prospective cohort study